Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
ALFA Insurance teams with Sorrell College of Business to create a business innovation lab to spur student success and develop the next generation of business leaders